Trial Profile
A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-100
- Sponsors Merck Sharp & Dohme Corp.
- 18 Oct 2023 Results of prespecified exploratory analysis evaluating the association of gene expression signatures, tumor mutational burden (TMB), and multiplex immunohistochemistry (mIHC) tumor microenvironment associated cell phenotypes with clinical outcomes of pembrolizumab in advanced recurrent ovarian cancer (ROC) , published in the Gynecologic Oncology
- 15 Apr 2021 Status changed from active, no longer recruiting to completed.
- 09 Apr 2021 The trial has been completed in Poland, according to European Clinical Trials Database record